Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VEGF-Trap in Recurrent or Persistent Endometrial Carcinoma
NCT00462826Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Nov 2007
- Primary completion
- Jan 2013
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of aflibercept in endometrial carcinoma, sponsored by National Cancer Institute. Started Nov 2007; status: completed.
02
Drugs
aflibercept
03
Conditions
endometrial carcinoma
Beyond the preview
Go deeper on NCT00462826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00462826.